Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AMRI Advances IBS Drug | Contract Pharma

What are you searching for?

Sign in

AMRI Advances IBS Drug

AMRI has selected a compound from its research program for the treatment of irritable bowel syndrome (IBS) to advance to preclinical testing.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AMRI has selected a compound from its research program for the treatment of irritable bowel syndrome (IBS) to advance to preclinical testing. The company plans to submit an IND with the FDA in 2011.

AMRI’s drug candidate is a 5-HT3 receptor partial agonist shown to moderate the function of 5-HT3 receptors, which is an approach that could be particularly beneficial in treatment of the non-constipation forms of IBS.

“We are pleased to announce another significant achievement emerging from our R&D efforts, this on the heels of the news that an AMRI anti-obesity compound was entered into Phase I testing in July,” said chairman, chief executive officer and president Thomas E. D’Ambra, Ph.D.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters